Antimicrobial Susceptibility Testing Market Poised to Reach New Heights as Infections Rise

-

The antimicrobial susceptibility testing market is projected to reach USD 4.7 Billion in 2027 from 3.6 Billion in 2022 at a CAGR of 5.5% during the forecast period. The high prevalence of infectious diseases, rising government funding and initiatives for antimicrobial susceptibility testing programs, technological developments for the creation of new AST methods, and the emergence of multidrug resistance in microorganisms are the main factors driving the antimicrobial susceptibility testing market. However, strict government controls are anticipated to limit this market's expansion to some degree. Players in the antimicrobial susceptibility testing market may anticipate having tremendous growth potential as a result of emerging markets and ongoing R&D to provide quick antimicrobial susceptibility testing.

The Antimicrobial susceptibility testing market is moderately competitive, with both established companies and upcoming competitors for the same market share. As of 2021, the key players operating in the Antimicrobial susceptibility testing market are bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US), Merck KGaA (US), HiMedia Laboratories (India), Liofilchem S.R.L Diagnostics (Italy), Alifax S.r.l. (Italy), Creative Diagnostics (US), Synbiosis (UK), Bioanalyse (Turkey), ZHUHAI DL BIOTECH Co., Ltd. (China), ELITechGroup (France), Mast Group Ltd. (UK), CONDALAB (Spain), Genefluidics, Inc. (US), Biotron Ltd. (Australia), InvivoGen (US), MP Biomedicals (US), QuantaMatrix Inc. (South Korea), and PML Microbiologicals Inc. (US), among others.

To further increase their market share in the Antimicrobial susceptibility testing market, these competitors have utilized a variety of strategies, including acquisitions, agreements, partnerships, and product releases. In 2022, a higher share of the Antimicrobial susceptibility testing market was held by bioMérieux SA (France), Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Danaher Corporation (US), and Bio-Rad Laboratories, Inc. (US)

Opportunities: Growth opportunities in emerging market

Emerging countries such as APAC,India, China and Japan  present significant opportunities for players operating in the Antimicrobial susceptibiity testing market. The demand for Antimicrobial susceptibiity testing market in these countries is increasing owing to rapid growth in medical tourism, the growing adult (aged 20 and above) population, increasing drug abuse. These countries are also home to a strong and qualified workforce and have a great knowledge of advance technologies.Furthermore, these countries have lenient policies for imports/exports and are underpenetrated in most aspects, which could help companies in brand development. Increasing developing technicians and the keen to know about new technologies is helping the regions to grow and update their technologies.

Drivers: Emergence of multidrug resistance due to drug abuse

As medication resistance increases internationally, making diseases harder to cure and ultimately to mortality, antibiotics are becoming less and less effective. According to the WHO priority pathogen list, new antibiotics are urgently needed, for instance, to treat carbapenem-resistant gram-negative bacterial infections. Unfortunately, these novel medicines will experience the same destiny as the present antibiotics and become useless if people do not modify the way antibiotics are used currently.

Related Links

https://www.marketsandmarkets.com/Market-Reports/antimicrobial-susceptibility-testing-market-206359984.html

https://www.marketsandmarkets.com/PressReleases/antimicrobial-susceptibility-testing.asp

https://www.marketsandmarkets.com/ResearchInsight/antimicrobial-susceptibility-testing-market.asp

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more